Tianfeng Securities released a research report on April 8 stating that it maintains Huitai Healthcare's (688617.SH) purchase rating. The main reasons for the rating include: 1) all business segments go hand in hand to help improve future performance; 2) increasing R&D and reasonably controlling cost growth to help long-term development; 3) integrating M&A investment and internal resources to focus on building a diversified competitiveness matrix. (Mainichi Keizai Shimbun)
天风证券4月8日发布研报称，维持惠泰医疗（688617.SH）买入评级。评级理由主要包括：1）各业务板块齐头并进，市场拓展和产品创新助力未来业绩提升；2）研发加码与合理控制费用增长，助力长期发展；3）并购投资与内部资源整合，着力构建多元化的竞争力矩阵。（每日经济新闻）
Tianfeng Securities released a research report on April 8 stating that it maintains Huitai Healthcare's (688617.SH) purchase rating. The main reasons for the rating include: 1) all business segments go hand in hand to help improve future performance; 2) i
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated